Thursday, April 24, 2014

Reform Clause Could Cripple Large Drug Manufacturers In Fraud Suits

An approximately 150-word provision in health care reform legislation could have major and debilitating ramifications on the availability of drugs by prohibiting large corporations from participating in state Medicaid programs if a subsidiary or affiliate's products are banned from reimbursement under those plans, industry sources said.

You've followed a link to an article or document on
There are three ways you can access this content.

Subscriber Login

If you are an subscriber, or you have an active trial subscription, please login here:

Take A Trial Subscription

If you haven't already had a trial subscription to, you can sign up for one right now. Just click on the link below to get started -- you'll get full access for one month, including access to our newsletters, Inside CMS and FDA Week, plus daily news updates by e-mail and much, much more.

Sign up for a trial subscription.

Buy This Article

You can also buy this and other individual articles by going to the NewsStand. Articles are $5 apiece. We'll even give you your first download free.

Here's a direct link to this article on the NewsStand.